The Hatch Waxman Act and the Biological Price Competition and Innovation Act have incentivized efforts to improperly prolong ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Budget cuts, delays to grant reviews, and layoffs of federal workers at agencies like the NIH and the National Science Foundation have affected nearly every research organization in the US. If ...

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...

Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...

A team of chemists, biologists and microbiologists led by researchers in Arts & Sciences at Washington University in St.

Every few days, doctors needed to drain liters of fluid ... There isn’t typically much money to be made developing a new drug ...